Net Sales are expected to increase by 7.5 percent Q-o-Q (up 7.3 percent Y-o-Y) to Rs 2512.6 crore, according to KR Choksey. ...http://www.moneycontrol.com/news/brokerage-results-estimates/cadila-healthcare-q3-pat-seen95-to-rs-3696-cr-kr-choksey_8260921.html
Drug firm Zydus Cadila has received approval from the USFDA to market tizanidine hydrochloride capsules, a muscle relaxant, in the American market.... ...http://www.business-standard.com/article/pti-stories/zydus-cadila-gets-usfda-nod-to-market-muscle-relaxant-in-us-117030800303_1.html
Cadila Healthcare today said that it has finalised a pact with Supernus Pharmaceuticals to settle patent litigation regarding Trokendi XR... ...http://www.business-standard.com/article/pti-stories/cadila-inks-pact-with-supernus-pharma-to-settle-patent-issue-117030700415_1.html
Posted by Equitymaster Global markets ended on a mixed note in the week gone by. While markets in the developed economies ended in green, the... ...http://feeds.equitymaster.com/~r/TodaysMarket/~3/HcnPkU-K9MI/tm.asp
Ahmedabad-headquartered Cadila Healthcare has today informed the Bombay Stock Exchange (BSE) that its Baddi plant has received three observations... ...http://www.business-standard.com/article/companies/usfda-observations-on-baddi-plant-unlikely-to-have-much-impact-on-cadila-117030200757_1.html
The company was formed way back in...